Evidence map›Paper›PMID 42332158›Full record

ArticleDigestive diseases and sciences2026

Recompensation and Further Decompensation After Index Decompensation in Patients with Autoimmune Hepatitis: A Real-World Study.

Arnav Aggarwal, Sagnik Biswas, Sarthak Saxena, Ayush Agarwal, Shekhar Swaroop, Umang Arora, Shubham Jain, Samagra Agarwal, Shalimar

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Arnav AggarwalDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Delhi, India.
Sagnik BiswasDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Delhi, India.
Sarthak SaxenaDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Delhi, India.
Ayush AgarwalDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Delhi, India.
Shekhar SwaroopDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Delhi, India.
Umang AroraDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Delhi, India.
Shubham JainDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Delhi, India.
Samagra AgarwalDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Delhi, India.
ShalimarDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Delhi, India. drshalimar@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsThere are limited data on hepatic recompensation in autoimmune hepatitis (AIH)-related decompensated cirrhosis. We evaluated incidence and predictors of recompensation and further decompensation, and assessed the impact of recompensation on survival.

methodsIn this retrospective analysis of a prospectively maintained database, we included patients with AIH-related decompensated cirrhosis, confirmed by liver biopsy, who were treated with immunosuppression. Recompensation, defined by Baveno VII criteria (including etiological suppression), was analyzed using Fine and Gray competing-risk model with death as competing events. Secondary outcomes were all-cause mortality and further decompensation.

resultsAmong 112 patients (71% women; mean age 41 ± 13 years), 75% had ascites, 26% had variceal bleeding, and 13% had hepatic encephalopathy; median MELD-Na and CTP scores were 15.7 and 7, respectively. Prednisolone, azathioprine, and mycophenolate mofetil were used in 89%, 62% and 21% of patients, respectively. Over a median follow-up of 29 months, 60 (54%) patients achieved recompensation. Younger age, lower CTP score, and biochemical response at 6 months independently predicted recompensation, with biochemical response being the strongest predictor (sHR 1.75, 95% CI 1.02-2.88). After recompensation, 9 (15%) patients developed further decompensation (1- and 2-year incidence of 3.4% and 8.5%), whereas among 52 non-recompensated patients, 36 (69%) developed further decompensation and 16 (31%) remained in a stable decompensated state. Recompensation was associated with reduced mortality (HR 0.22, 95% CI 0.05-0.90) compared with non-recompensated patients.

conclusionOver half of treated AIH-related decompensated cirrhosis can achieve recompensation with immunosuppression, which is associated with reduced mortality. Younger age, lower CTP score, and biochemical response predict recompensation.

Indexed as

Hepatitis, AutoimmuneImmunosuppressive AgentsLiver CirrhosisAdultAscitesAzathioprineFemaleHepatic EncephalopathyHumansMaleMiddle AgedMycophenolic AcidPrednisoloneRetrospective StudiesRisk FactorsAzathioprineImmunosuppressive AgentsMycophenolic AcidPrednisoloneChronic liver diseaseImmunologyImmunosuppressionPortal Hypertension

Identifiers

PMID42332158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.